BioSpace News Archive

TeraImmune, Inc., a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to commence the Company’s Phase 1/2a clinical trial to evaluate its lead candidate, TI-168, in congenital Hemophilia A (HA) patients with refractory inhibitors.

Selecta Biosciences, Inc. today announced three upcoming presentations, including one joint presentation with our partner AskBio, at the 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference.

Adaptive Biotechnologies Corporation announced a partnership with Epic to integrate the clonoSEQ® Assay into Epic’s comprehensive electronic medical record system.

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced data demonstrating the potential of the Company’s novel platform to use various base editing strategies to successfully delete multiple cell surface targets from hematopoietic stem cells (HSCs), potentially enabling next-generation transplants for the treatment of acute myeloid leukemia (AML).

Xtant Medical Holdings, Inc. today announced the closing of the second and final tranche of its previously announced private placement with a select group of accredited investors led by Stavros Vizirgianakis.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced positive written feedback from the U.S. Food and Drug Administration (FDA) for its initial End-of-Phase 2 (EoP2) meeting request to discuss Chemistry, Manufacturing, and Controls (CMC) for its AQST-109 epinephrine sublingual film for the treatment of severe allergic reaction including anaphylaxis.

Procaps Group, a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced the completion of its inaugural 2021 ESG Annual Report, a comprehensive overview of environmental, social and governance metrics and corresponding strategies and initiatives for ESG priorities.

IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (“IceCure”, “IceCure Medical” or the “Company”) the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its ProSense Cryoprobes and Introducers have received regulatory approval from the Brazilian Health Regulatory Agency (“ANVISA”).

Incyte announced that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, November 1, 2022.

Dr. Reddy’s largest manufacturing facility in Bachupally, Hyderabad, joins Global Lighthouse Network of the World Economic Forum Journey started four years ago with digitisation of infrastructure and processes.